1. Home
  2. DOUG vs MDWD Comparison

DOUG vs MDWD Comparison

Compare DOUG & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOUG
  • MDWD
  • Stock Information
  • Founded
  • DOUG 1911
  • MDWD 2000
  • Country
  • DOUG United States
  • MDWD Israel
  • Employees
  • DOUG N/A
  • MDWD N/A
  • Industry
  • DOUG Building operators
  • MDWD Medicinal Chemicals and Botanical Products
  • Sector
  • DOUG Real Estate
  • MDWD Health Care
  • Exchange
  • DOUG Nasdaq
  • MDWD Nasdaq
  • Market Cap
  • DOUG 166.2M
  • MDWD 179.1M
  • IPO Year
  • DOUG N/A
  • MDWD 2014
  • Fundamental
  • Price
  • DOUG $1.82
  • MDWD $17.80
  • Analyst Decision
  • DOUG
  • MDWD Strong Buy
  • Analyst Count
  • DOUG 0
  • MDWD 1
  • Target Price
  • DOUG N/A
  • MDWD $28.00
  • AVG Volume (30 Days)
  • DOUG 676.3K
  • MDWD 60.7K
  • Earning Date
  • DOUG 11-05-2024
  • MDWD 08-14-2024
  • Dividend Yield
  • DOUG N/A
  • MDWD N/A
  • EPS Growth
  • DOUG N/A
  • MDWD N/A
  • EPS
  • DOUG N/A
  • MDWD N/A
  • Revenue
  • DOUG $951,674,000.00
  • MDWD $20,141,000.00
  • Revenue This Year
  • DOUG $3.85
  • MDWD $30.16
  • Revenue Next Year
  • DOUG $17.40
  • MDWD $18.44
  • P/E Ratio
  • DOUG N/A
  • MDWD N/A
  • Revenue Growth
  • DOUG N/A
  • MDWD N/A
  • 52 Week Low
  • DOUG $1.00
  • MDWD $7.45
  • 52 Week High
  • DOUG $3.16
  • MDWD $24.00
  • Technical
  • Relative Strength Index (RSI)
  • DOUG 54.58
  • MDWD 50.02
  • Support Level
  • DOUG $1.42
  • MDWD $16.25
  • Resistance Level
  • DOUG $1.91
  • MDWD $17.90
  • Average True Range (ATR)
  • DOUG 0.17
  • MDWD 0.97
  • MACD
  • DOUG -0.01
  • MDWD -0.05
  • Stochastic Oscillator
  • DOUG 61.01
  • MDWD 36.98

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: